Evolution Bio

Summary

Evolution Bio is a Salt Lake City biotechnology company, founded circa 2022, built around directed protein evolution for drug discovery — especially G-protein coupled receptors (GPCRs). GPCRs are the highest-value target class in pharmacology — roughly a third of approved drugs act on them — and among the hardest to engineer.

Impact

GPCRs are the highest-value target class in pharmacology — roughly a third of approved drugs act on them — and among the hardest to engineer, because variants selected in bacteria or yeast frequently behave differently in mammalian pharmacology. VEGAS attacks that mismatch directly by performing selection in mammalian cells, with reported 24-hour selection cycles and week-scale campaigns across transcription factors, GPCRs, and nanobodies. A commercial platform that reliably delivers mammalian-evolved GPCR variants would compress discovery cycles across an enormous target space, and the depth of that displacement is what puts the page in the middle of the ladder rather than the bottom.

Two discounts keep it there. First, the ceiling belongs to the field, and a page gets the share it would actually cause: mammalian directed evolution has several credible pursuers — yeast-based GPCR evolution and vaccinia-based mammalian systems among them — so "if this works, drug discovery changes" is not the same claim as "if we are the ones who make it work." Second, VEGAS was published in Cell in 2019 and its components are available on Addgene, which means the method is not the moat; the company's counterfactual contribution is industrializing something an adequately funded lab could otherwise run itself. Independent reviews have also questioned continuous Sindbis-based evolution on packaging competition, cheater emergence, and alphavirus biosafety — real limits on claiming production readiness.

Bet: that selection pressure applied in mammalian cells produces protein variants that survive the translation to human pharmacology often enough to be worth buying, and that a services-and-licensing platform is the right business shape for capturing that value rather than a single-asset drug company.

What They Are Building

Evolution Bio's model, inferred from investor and incubator descriptions rather than from company documents, is platform infrastructure: apply directed evolution to partners' therapeutic candidates across target classes, through licensing or contract engineering, rather than developing a proprietary drug pipeline. Altitude Lab describes it as "a biotechnology company using its directed evolution technology to optimize drug candidates across a broad range of therapeutic targets," and third-party profiles add laboratory automation, iterative selection, and data-driven screening as the operating method.

The English Lab continues active VEGAS expansion — new selection paradigms, nanobody libraries for GPCR control, GPCR pharmacogenomics — which plausibly feeds the company's technology base. Where the corporate IP boundary sits relative to ongoing academic work is not documented in any source cited here.

What They Need Now

Likely needs are protein engineers and molecular biologists fluent in mammalian cell culture and viral vector systems, GPCR pharmacology specialists, synthetic-biology engineers, pharma business-development leaders who have sold platform tools, and patent counsel for licensing. The structural need is different and more urgent: a reference customer or announced partnership that demonstrates repeatability beyond the original published demonstrations, and any public artifact — a live website, a funding announcement, a press release — establishing that the company is operating.

Who Could Help

GPCR structural biology advisors; pharma discovery executives with platform-tool procurement experience; viral-vector biosafety consultants who can speak to the alphavirus concerns; and investors who price tool-company economics rather than therapeutic multiples. Altitude Labs infrastructure and network remain relevant given its listed investment.

Utah Context

Evolution Bio is a University of Utah biochemistry spinout backed by Utah's Nucleus Fund, the university itself, and Altitude Lab, the Recursion-affiliated incubator in University of Utah Research Park. It connects the state's academic GPCR pharmacology depth to the Wasatch Front's platform-biotech cluster, and it is one of the smaller entries in an Altitude Lab portfolio — 52 companies across residents and alumni — that is the main engine turning University of Utah life-science research into companies.

Evidence

• Altitude Lab portfolio · https://altitudelab.org/portfolio — lists Evolution Bio as an alumnus, established 2022, in the therapeutics category, with the company description quoted above.
• VEGAS as a Platform for Facile Directed Evolution in Mammalian Cells · https://pubmed.ncbi.nlm.nih.gov/31280962/ — the peer-reviewed basis for the platform.
• English Lab (University of Utah) · https://www.english.biochem.utah.edu — the academic program and its continuing VEGAS work.
• Justin English faculty profile, University of Utah · https://medicine.utah.edu/faculty/justin-g-english — the scientific founder's position and research areas.
• Evolution Bio company profile, PitchBook · https://pitchbook.com/profiles/company/589414-06 — founding year, Salt Lake City headquarters, and the investor list (Nucleus Fund, University of Utah, Altitude Lab).

See Also

• Intactis Bio — another early Altitude Lab–associated Utah deep-tech company.
• Altitude Labs — the incubator listed as an investor.

Open Questions

• Is the company operating? Altitude Lab lists it as an alumnus, which may mean graduated or wound down. Its BioUtah member listing now returns HTTP 410 Gone (checked 2026-08-13), and the evobio.com domain that Altitude Lab gives serves a near-empty page. Nothing found establishes activity after the seed-stage backing.
• No usable official website. **Website:** is deliberately unset rather than pointing at the English Lab, which is the academic lab and not the company. Note that evobiologics.com is a different company entirely and should not be conflated with this one.
• A site at discovery-evolution.com describes a "digital directed evolution" GPCR antibody platform and may be a rebrand, a successor, or unrelated — the relationship is unverified.
• Pharma partnerships unverified. Eli Lilly and Kallyope partnerships have been reported; no captured primary source confirms them. Treat as unverified until a press release or filing establishes them. (Note that Eli Lilly acquired a differently named directed-evolution company, Applied Molecular Evolution, in 2004 — a plausible source of confusion.)
• Corporate versus academic IP boundary. How much VEGAS IP and ongoing development sit in Evolution Bio rather than the English Lab is unclear without licensing or cap-table records.
• Funding amount and valuation beyond investor names are not public in sources reviewed.
• Careers URL: no public employer careers board found (2026-08-13).